AMSTERDAM, The Netherlands, October 22 /PRNewswire/ -- Agendia BV, a world leader in the rapidly evolving field of cancer molecular diagnostics, announced today that its Chief Research Officer Laura van ‘t Veer has received a prestigious 2007 Breast Cancer Research Foundation Award from the Pink Ribbon Breast Cancer Research Foundation.
The Pink Ribbon ‘Breast Cancer Research Foundation’ granted in New York awards to 151 international breast cancer researchers with a total value of 32 M$.
Laura van ‘t Veer received one of the awards together with her colleagues Martine Piccart-Gebhardt, Fatima Cardoso and Beppe Viale for their work on the European ‘MINDACT’ trial in which specific predictive aspects of MammaPrint(R) breast cancer prognosis assay are further tested.
Since inception in 1993 by Evelyn Lauder, the Breast Cancer Research Foundation has been solely dedicated to providing critical funding for innovative clinical and genetic research at leading medical centers worldwide.
“Laura is deeply committed to convert discoveries made in the academic setting into clinically-relevant products for the benefit of cancer patients. She co-founded Agendia exactly for that purpose. Her meticulous work enabled Agendia to become the first company to obtain clearance from the US FDA for its MammaPrint(R) breast cancer test. We are very pleased to have her and other people of her caliber in our team”, said Dr. Bernhard Sixt, CEO of Agendia.
About Agendia
Agendia, located in Amsterdam, the Netherlands, is a world leader in gene expression analysis-based diagnostics with three products on the market. The company focuses on the development and commercialization of diagnostic tests using tumor gene expression profiling. Agendia was the first company to commercialize a prognostic test - MammaPrint(R) - that predicts the risk of breast cancer recurrence. Its second microarray product, CupPrint(R)(x), is a diagnostic test to identify the origin of a metastasis in a cancer type called “Cancer of Unknown Primary”. Agendia recently also presented its new colon cancer prognosis profile, ColoPrint(R), which is currently undergoing further validation
Agendia maintains close ties with several leading academic centers to develop state of the art diagnostic tests for cancer. Agendia also offers its expertise to pharma companies focusing on development of highly effective personalized drugs in the area of oncology.
(x) CupPrint(R) is based on a license to the TUA database of AviaraDx
CONTACT: Contact Information: Agendia: Laura van ‘t Veer, CRO at
+31-20-512-9161.
